
Protein Inhibitor Of Galectin-3 To Limit Fibrosis After Myocardial InfarctionAward last edited on: 9/9/14
Sponsored Program
SBIRAwarding Agency
NIH : NHLBITotal Award Amount
$299,958Award Phase
1Solicitation Topic Code
-----Principal Investigator
Constance M JohnCompany Information
Phase I
Contract Number: 1R43HL120645-01Start Date: 9/4/13 Completed: 8/31/14
Phase I year
2013Phase I Amount
$299,958Public Health Relevance Statement:
Public Health Relevance:
Myocardial infarction (MI) is the most common cause of cardiac morbidity and mortality in the western world, and is responsible for 1 out of 6 deaths (~400,000) in the US per year. Currently, the main mortality associated with coronary events is due to subsequent heart failure. This project aims to limit excess fibrosis and adverse remodeling after MI and is expected to lead to improved outcomes and have a major impact on the mortality associated with cardiovascular disease.
NIH Spending Category:
Cardiovascular; Heart Disease; Heart Disease - Coronary Heart Disease
Project Terms:
Acute myocardial infarction; Adrenal Cortex Hormones; adverse outcome; Affinity; Allergic Reaction; Althaea; Amino Acids; angiogenesis; animal data; Animal Model; Anti-inflammatory; Anti-Inflammatory Agents; Appearance; Architecture; Arteries; Azathioprine; base; Binding (Molecular Function); Biological Assay; Biological Availability; Biological Markers; Carbohydrates; Cardiac; Cardiac Myocytes; Cardiovascular Diseases; Cessation of life; Characteristics; Chimeric Proteins; Chronic; Cicatrix; Clinical Trials; Colchicine; Collagen; commercialization; Coronary; Development; Diagnostic; Digestion; Dominant-Negative Mutation; Dose; Drug Formulations; Drug Kinetics; effective therapy; Europe; Event; Family; Fibroblasts; Fibrosis; Functional disorder; Galactose Binding Lectin; Galactosides; Galectin 3; Glycoconjugates; Goals; Half-Life; Heart; Heart failure; Hour; Human; Human body; Immune; improved; In Vitro; in vivo; Incidence; Inflammation; inhibitor/antagonist; Injury; Ischemia; Kidney; Lead; Learning; Lectin; Ligands; Marketing; Mediating; Mediator of activation protein; Modeling; Morbidity - disease rate; Mortality Vital Statistics; Mus; Mutant Strains Mice; Myocardial Infarction; Myofibroblast; Operative Surgical Procedures; Oral; Organ; Organ failure; Organ Transplantation; Outcome; Patients; Peptide Hydrolases; Pharmaceutical Preparations; Phase; Plasma; Process; Production; Prostate-Specific Antigen; Proteins; public health relevance; Pump; Rattus; Reperfusion Therapy; Research; research study; response; Risk; Serum; Severities; Subcutaneous Injections; Testing; Therapeutic; Time; Tissues; Toxic effect; Toxicology; Western World; Wound Healing
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00